All In Biotech

Drug Trial Radar · NCT06592417

To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors

Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Apr 30, 2024

Primary completion

May 17, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I open, multi-center, first-in-human study evaluating JSKN016 in subjects with advanced metastatic solid tumors, divided into dose escalation and dose extension.

Conditions

  • Advanced Malignant Solid Tumor

Interventions

  • JSKN016 injectionDrug

    JSKN016 is a bispecific antibody drug conjugate targeting HER3 and TROP2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of DLTsTime frame: 21 days after the first dose for subjects at dose escalation stage
  2. The frequency and severity of treatment-related adverse events (TEAE), treatment-related adverse events (TRAE), and serious adverse events (SAE).Time frame: From first dose to 30 days after last dose
  3. MTD or RP2D of JSKN 016Time frame: Postdose of last participant up to 1 year
  4. Objective Response Rate (ORR) in Extended queueTime frame: Postdose of last participant up to 1 year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Sun Yat-sen Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.